iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies.
The Company is targeting two key resistance pathways to checkpoint therapy: adenosine and regulatory T cells (Tregs). The Company’s lead program, EOS-850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS-448), is expected to enter the clinic in first quarter of 2020.
iTeos Therapeutics is headquartered in Cambridge, MA with a world-class research center in Gosselies, Belgium. The Company was founded by the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain).
In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Earlier investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round.